Director, Metabolic Disease Discovery Research

What if… you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies to transform human health and sustainability?

Flagship Pioneering's venture creation engine has conceived and created companies such as Moderna Therapeutics (NASDAQ: MRNA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, and Tessera Therapeutics. Since its launch in 2000, Flagship has applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $212 billion in aggregate value. To date, Flagship has deployed over $2.5 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. In 2021, Flagship Pioneering was ranked 12th globally on Fortune’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies.

The Company:

Quotient Therapeutics, Inc. is a privately held, early-stage company developing a novel genomics platform and therapeutics for diseases with a large unmet need.

Position Summary:

Seeking a talented and highly motivated Director in Metabolic Disease Discovery Research to play a vital role in the company’s efforts to progress lead candidates to IND and early clinical studies. The candidate will direct all drug discovery research activities from lead generation to IND and contribute to early clinical studies related to the programs. The successful candidate will work closely with the Quotient leadership team and scientists, as well as the Flagship Pioneering team to rapidly advance the drug discovery programs. They will be comfortable working in and contributing to a highly dynamic and cross-functional team environment. The ideal candidate must be independent, open-minded, goal-oriented, have excellent communication skills and work in a fast-paced entrepreneurial environment.

Responsibilities:

• The Program Leader in Metabolic Diseases Research will direct all drug discovery research activities from lead generation to IND and contribute to early clinical studies related to the programs
• Play a leading role in selecting new indications in Metabolic Diseases for exploratory work (in addition to driving existing projects)
• Work cross functionally towards a continuous output of development compounds which address the unmet medical need in various disease indications within the Metabolic area.
• Build and manage an attractive program portfolio and help to establish Quotient Tx as a recognized and competitive company in the Metabolic Disease area
• Actively support and pursue necessary external collaborations
• Lead cross-functional program teams, relying on expertise from across on company and interface with various current and future teams at Quotient, such as Medicinal Chemistry, Platform Biology, Development (DMPK, Preclinical Drug Safety, Clinical Pharmacology and Medicine) and with the Quotient leadership team
  
  

Qualifications:

• PhD scientist with profound knowledge of Metabolic Diseases across multiple indications, including liver diseases, diabetes, obesity, and rare metabolic disorders
• Ideally strong experience in Pharmacology and Physiology
• Scientific curiosity and ability to think strategically
• Previous relevant experience in pharma or biotech drug discovery for at least 5 years, as well as a comprehensive understanding of drug development
• Contributed to multiple drug discovery programs from lead generation (or hit-to-lead) through IND in Metabolic Diseases
• Experience with IND enabling studies and compiling regulatory study reports for IND submission
• Proven track record in driving collaborative approaches in drug discovery with internal as well as external partners
• Strong teaming experience in a matrix environment
  
  

Location: Cambridge, MA

About Flagship

Flagship Pioneering is a bioplatform innovation company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture. Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com.

Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

At Flagship, we recognize there is no perfect candidate. If you have some of the experience listed above but not all, please apply anyway. Experience comes in many forms, skills are transferable, and passion goes a long way. We are dedicated to building diverse and inclusive teams and look forward to learning more about your unique background.

Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.